.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AE06_InsulinDegludec.InsulinDegludec

Information

Insulin degludec is a long-acting human insulin analog used in the management of diabetes mellitus in adults, adolescents, and children aged 1 year and above. It is approved for once-daily subcutaneous administration and achieves a flat and stable pharmacokinetic profile, allowing for flexible dosing intervals.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult subjects with type 1 and type 2 diabetes after subcutaneous administration.

References

1. Rendell, M (2013). Insulin degludec: a long-acting modern insulin analogue with a predictable pharmacokinetic/pharmacodynamic profile. Drugs of today (Barcelona, Spain : 1998) 49(6) 387–397. DOI:10.1358/dot.2013.49.6.1976051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23807942

2. Tumini, S, et al., & Cipriano, P (2020). Insulin/carbohydrates ratio during the first 6-month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study. Endocrinology, diabetes & metabolism 3(2) e00121–None. DOI:10.1002/edm2.121 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32318639

3. Liu, H, et al., & Yu, Y (2025). Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Drug design, development and therapy 19 2863–2871. DOI:10.2147/DDDT.S500347 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40236299

Revisions

• 06/2025 initial generated model